Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.73 |
| ▸ | DRD2 | P14416 | 12/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348713 | 0.85 | DRD3 (1.00) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL14289423 | 0.83 | DRD3 (0.69) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL24877483 | 0.82 | DRD3 (0.75) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL4875328 | 0.80 | DRD2 (0.67) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL16846477 | 0.78 | HRH3 (0.47) | DRD3DRD2USP30 | |
| SCHEMBL12314095 | 0.78 | DRD3 (0.58) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL10295474 | 0.78 | DRD3 (0.58) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL31523251 | 0.77 | DRD2 (0.73) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL7351002 | 0.76 | DRD3 (0.85) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL13197442 | 0.76 | DRD3 (0.58) | DRD3DRD2CYP2D6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | DRD3 2843/4885DRD2 3230/4885CYP2D6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.